Global Bispecific Antibody Therapeutics Market Size By Indication(oncology, autoimmune disease), By End-Users(hospitals, specialty clinics, home care), By Geographic Scope And Forecast

Bispecific Antibody Therapeutics Market Size And Forecast

Bispecific Antibody Therapeutics Market size was valued at USD 523.9 Million in 2021 and is projected to reach USD 963.3 Million by 2030, growing at a CAGR of 7.0% from 2022 to 2030.

The rise in cancer prevalence rates around the world will perform as a primary driver, causing the market’s growth rate to expand. The Global Bispecific Antibody Therapeutics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

What is Bispecific Antibody Therapeutics?

Bispecific antibodies? They're like the superheroes of the antibody world! Imagine an antibody that can latch onto two different things at once, maybe two totally separate targets or just different spots on the same one. They're proving to be absolute rockstars when it comes to helping your immune system take down cancer. Think of them as giving immune cells a direct order to attack cancer cells, often using cool tricks like antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). Because they're so versatile and we can make them in so many different ways, bispecific antibodies have HUGE potential as treatments. And get this – thanks to advancements in protein and antibody engineering, we've cooked up around 50 brand new types of them in just the last few years!

Moreover, bispecific antibodies have two antigen-binding sites in a single molecule. Bispecific antibodies come in a wide range of sizes and forms, from small proteins with two antigen-binding fragments to large IgG-like molecules with extra domains. Bispecific antibody development in oncology has accelerated because of the therapeutic success of currently existing bispecific antibodies. There are 106 bispecific antibody molecules in development, according to Global data’s database. The majority of the 106 bispecific antibody medicines in clinical development target blood cancers, whereas the rest target solid tumors, primarily lung and gastrointestinal cancers.

So far, we've got two bispecific antibodies approved for use as medicineBlincyto (back in 2014) and Hemlibra (in 2017). And get this – in 2019 (up to September), Blincyto made USD 232 million, while Hemlibra raked in USD 930 million! It seems like everyone's getting interested in bispecific antibodies; there's been a huge jump in clinical trials, from just 51 in 2014 to over 300 in 2019.

Right now, there are over 300 potential bispecific drugs being tested in clinical or preclinical trials. Plus, lots of drug companies and tech developers have been signing deals lately to speed up the creation of new drugs.

Global Bispecific Antibody Therapeutics Market Overview

Okay, so cancer rates are climbing, and that's a big deal because we're going to need better treatments. The World Health Organization (WHO) says cancer is the second leading cause of death globally, right behind heart disease! But here's the thingit's also one of the most preventable long-term illnesses. Ditching the smoking habit, eating better, and getting some exercise could prevent up to 40% of cancer deaths! Sadly, a lot of people are living a more sedentary lifestyle, and that raises the risk. Plus, all that processed food isn't doing anyone any favors. So, with more unhealthy lifestyles, cancer rates are going up, and we need better treatments ASAP. And guess what? Increased healthcare spending is also boosting the bispecific antibody therapeutics market, which means more options for those who need them. Government agencies are stepping up, investing in better healthcare, which is a game-changer. Finally, with increased awareness programs and a growing elderly population, the bispecific antibody therapeutics market is only going to expand. So, between unhealthy habits and helpful government policies, this market is looking at some major growth!

On the other hand, during the forecast period of 2022-2030, the high cost of drug development will stifle the growth rate of the bispecific antibody therapeutics market. The market for bispecific antibody therapeutics would be challenged by a lack of healthcare infrastructure in developing nations and a stringent regulatory environment. Additionally, during the projection period of 2022-2030, a lack of public awareness and poor reimbursement policies may constrain and impede the market’s growth rate.

Global Bispecific Antibody Therapeutics MarketSegmentation Analysis

The Global Bispecific Antibody Therapeutics Market is segmented based on Indication, End-Users, and Geography.

Bispecific Antibody Therapeutics Market by Indication

• Oncology• Autoimmune Disease• Others

Alright, so let's talk Indication. The market's really driven by a few big areasfirst, there's oncology, which is everything cancer-related. Then we've got autoimmune diseases, and after that, just a bunch of "others". Now, cancer's a massive deal – the World Health Organization says it's the second biggest cause of death worldwide, only after heart disease. And check this outso many people are living really inactive lives. Makes sense that less movement could lead to more cancer, right? Plus, all the unhealthy food we grab when we're chilling out isn't helping. Basically, if more people keep living like this, we're probably going to see even more cancer cases, which means we really need some better treatments. So, yeah, that oncology part of the market? It's probably going to keep growing because, sadly, there's just so much need for it.

Bispecific Antibody Therapeutics Market by End-Users

• Hospitals• Specialty Clinics• Homecare• Others

So, who's actually using these amazing new treatments? You'll find them in hospitals, specialty clinics, and even with people getting care at home, and a few other places, too. What's really making this happen is the incredible progress we're seeing with bispecific antibodies, especially when it comes to fighting cancer. Global data says there are a whopping 106 of these molecules being studied right now! And get thisthere are currently 263 clinical trials going on, all focused on bispecific antibodies. Of those 106 antibody agents being tested, 45 are aimed at blood cancers, and the rest are tackling solid tumors, particularly those in the stomach, intestines, and lungs. So, yeah, with all this research and so many trials, it's no wonder people are predicting big things for these therapies. There's a lot of hope that these antibodies could be a game-changer for treating all sorts of cancers!

Additionally, bispecific antibodies are being developed by market manufacturers in collaboration with regional biotech companies. These efforts by the manufacturers will also assist the global market for bispecific antibodies to grow at an extraordinary pace.

Bispecific Antibody Therapeutics Market by Geography

• North America• Europe• Asia Pacific• Rest of the World

If you glance at a world map, you'll see the Global Bispecific Antibody Therapeutics market is split into North America, Europe, Asia Pacific, and the rest of the world. At the moment, North America is leading the pack in terms of market size and revenue, and honestly, we don't foresee that changing anytime soon. What's driving this? The increasing demand for targeted therapies and rising healthcare expenditures are really boosting the market there. Not to mention, a lot of major companies are based in North America and they're adopting cutting-edge technologies, which is only going to accelerate things.

Additionally, due to an increase in cancer incidence in this region, Asia-Pacific is predicted to be the fastest-growing region throughout the forecast period of 2022-2030. Furthermore, the expansion of healthcare infrastructure as well as rising government efforts would accelerate the market’s growth rate in this area.

Key Players

The study of the “Global Bispecific Antibody Therapeutics Market” will provide useful information with a focus on the global market. The major players in the market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, AstraZeneca, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Allergan, Innovent Biologics, Inc., Adimab, Affimed GmbH, Xencor, Pieris Pharmaceuticals, Inc., Mereo BioPharma Group plc, Sobi, TG Therapeutics, Inc., Merus, MacroGenics, Inc., Emergent BioSolutions Inc., Genmab A/S, Alteogen, Astellas Pharma Inc. and among others.

The competitive landscape section also consists of market share, key development strategies, and market ranking analysis of the above-mentioned players globally.

Key Developments

So, Pfizer just kicked off a big Phase 2 study, MagnetisMM-3, to really put their drug Elranatamab (that's also PF-06863135) to the test. This drug is a pretty cool antibody designed to target BCMA and CD3. They're figuring out how well it works and how safe it is when given as a shot – specifically for those with multiple myeloma who've already been through the ringer with other treatments. And get this, the US Food and Drug Administration gave Elranatamab Fast Track Designation! Basically, they think it could be a big deal and are trying to speed up the approval process because it could offer real hope where there aren't a lot of great options right now.

• AstraZeneca entered into a long-term partnership with Samsung Biologics to strengthen its manufacturing capabilities and expand its biologics manufacturing capabilities into the Asia Pacific.

• Amgen Inc. announced the acquisition of Five Prime Therapeutics. The acquisition adds Five Prime’s innovative pipeline to Amgen’s leading oncology portfolio.

Report Scope

Top Trending Reports

Research Methodology of Market Research

<img alt="Research Methodology of " class="lazyloaded aligncenter wp-image-73269 size-full" data-lazy-sizes="(max-width2084px) 100vw, 2084px" data-lazy-src="https://www.marketresearch.com/wp-content/uploads/2020/10/Research-Methodology-.jpg" data-lazy-srcset="https://www.marketresearch.com/wp-content/uploads/2020/10/Research-Methodology-.jpg 2084w, https://www.marketresearch.com/wp-content/uploads/2020/10/Research-Methodology--100x180.jpg 100w, https://www.marketresearch.com/wp-content/uploads/2020/10/Research-Methodology--167x300.jpg 167w, https://www.marketresearch.com/wp-content/uploads/2020/10/Research-Methodology--768x1382.jpg 768w, https://www.ver